HighTide Therapeutics (HKSE:02511) FCF Yield % : -14.63 (As of May. 31, 2024)

View and export this data going back to 2023. Start your Free Trial

What is HighTide Therapeutics FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, HighTide Therapeutics's Trailing 12-Month Free Cash Flow is HK$-392.36 Mil, and Market Cap is HK$2,630.48 Mil. Therefore, HighTide Therapeutics's FCF Yield % for today is -14.63%.

The historical rank and industry rank for HighTide Therapeutics's FCF Yield % or its related term are showing as below:

HKSE:02511' s FCF Yield % Range Over the Past 10 Years
Min: -14.95 Med: 0 Max: 0
Current: -14.63

HKSE:02511's FCF Yield % is ranked worse than
50.71% of 1552 companies
in the Biotechnology industry
Industry Median: -14.35 vs HKSE:02511: -14.63

HighTide Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

HighTide Therapeutics FCF Yield % Historical Data

The historical data trend for HighTide Therapeutics's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HighTide Therapeutics FCF Yield % Chart

HighTide Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

FCF Yield %

-5.88

HighTide Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	-	-	-	-	-7.04

Competitive Comparison of HighTide Therapeutics's FCF Yield %

For the Biotechnology subindustry, HighTide Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HighTide Therapeutics's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HighTide Therapeutics's FCF Yield % distribution charts can be found below:

* The bar in red indicates where HighTide Therapeutics's FCF Yield % falls into.

HighTide Therapeutics FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

HighTide Therapeutics's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-392.36	/	6671.43216
	=	-5.88%

HighTide Therapeutics's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-234.878	*	2	/	6671.43216
	=	-7.04%

HighTide Therapeutics FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

HighTide Therapeutics FCF Yield % Related Terms

Thank you for viewing the detailed overview of HighTide Therapeutics's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

HighTide Therapeutics (HKSE:02511) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HighTide Therapeutics Inc (HKSE:02511) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Ganli Second Road, 18B-102, Zhonghaixin Innovation Industry City, Jihua Neighborhood, Longgang District, Guangdong, Shenzhen, CHN, 518112

Website

https://www.hightidetx.com

HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The company has developed a product pipeline of five product candidates in-house, covering nine indications in metabolic and digestive diseases among which, five are at clinical-stage. The Core Product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases.

Executives

Ma Lixiong	2101 Beneficial owner
Liu Liping	2101 Beneficial owner
Li Li	2201 Interest of corporation controlled by you
The Core Trust Company Limited
Shan Miao	2201 Interest of corporation controlled by you
Medi Prosperity Capital Inc.	2201 Interest of corporation controlled by you
Hepalink Healthcare Partners I L.p	2201 Interest of corporation controlled by you
Hepalink Biotechnology Ii Limited	2101 Beneficial owner
Hepalink (hong Kong) Limited	2201 Interest of corporation controlled by you
Shenzhen Hepalink Pharmaceutical Group Co., Ltd.	2501 Other
Wisdom Spring Group Limited
Tct (bvi) Limited
Baiyi Capital Limited	2101 Beneficial owner
Lai Hoi Man	2201 Interest of corporation controlled by you
Hongtu Capital Limited	2101 Beneficial owner

HighTide Therapeutics (HKSE:02511) Headlines

No Headlines